Medicare capped drug costs — but cancer patients still can’t afford their meds

Medicare capped drug costs — but cancer patients still can’t afford their meds

New research reveals that Medicare’s long-awaited prescription drug out-of-pocket cost cap is not enough to ensure access to lifesaving cancer medications, and many patients are still walking away from treatment. Key findings: Average upfront costs for a new specialty oral cancer drug still exceed $2,000 for many Medicare beneficiaries without low-income subsidies. While prescription fill rates improved after the policy change, fewer than half o